Vir Biotechnology Inc. (VIR)
XMEX 
NASDAQ (NGS) Primary XMEX Summary
VIR Chart
Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity
Vir Biotechnology is rated a buy, supported by a strong cash position, pivotal late-stage pipeline, and deep institutional backing. VIR's lead CHD drugs, Tobevibart and Elebsiran, target a large, underserved market with potential for high margins and accelerated regulatory approval. The Astellas partnership secures funding for oncology development, extends the cash runway into 2028, and minimizes dilution risk ahead of key catalysts.
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Vir Biotechnology Inc. (VIR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vir Biotechnology Inc. ever had a stock split?
Vir Biotechnology Inc. Profile
| Biotechnology Industry | Healthcare Sector | Marianne De Backer CEO | XMEX Exchange | US92764N1028 ISIN |
| US Country | 408 Employees | - Last Dividend | - Last Split | 11 Oct 2019 IPO Date |
Overview
Vir Biotechnology, Inc. is a forefront commercial-stage immunology company dedicated to developments in the field of serious infectious diseases prevention and treatment. Drawing upon a wide network of collaborations and agreements, Vir crafts innovative therapeutic products. The company has established grant agreements with prestigious organizations such as the Bill & Melinda Gates Foundation and the National Institutes of Health. It also boasts strategic alignments through option and license agreements with entities like Brii Biosciences Limited, alongside collaborations with industry giants including Alnylam Pharmaceuticals, Inc., WuXi Biologics, and GlaxoSmithKline. Furthermore, Vir Biotechnology has entered into manufacturing and clinical collaboration agreements with Samsung Biologics Co.,Ltd., and Gilead Sciences, Inc., respectively, focusing on the production and development of SARS-CoV-2 antibodies and treatments for chronic hepatitis B virus. Founded in 2016, Vir is headquartered in San Francisco, California, cementing its stature as a leader in immunology and infectious disease research.
Products and Services
- Sotrovimab (VIR-7832) under the Xevudy brand - This product is a groundbreaking therapeutic monoclonal antibody (mAb) engineered to treat and prevent COVID-19 infections by neutralizing the SARS-CoV-2 virus.
- VIR-2218 and VIR-3434 - These treatments are being developed to address the global health challenge of hepatitis B virus, potentially changing the treatment landscape for this chronic infection.
- VIR-2482 - Aimed at preventing influenza A virus, this prognostic tool represents Vir's dedication to tackling seasonal and pandemic flu threats, highlighting the company’s commitment to public health and preventive medicine.
- VIR-1111 - As an innovative approach to preventing the human immunodeficiency virus (HIV), this product underscores the company's focus on preventive therapies in the realm of global infectious diseases.
